Monday, 16 January 2017 11:29

PR: WILEX Signs Antibody License Agreement with Telix Pharmaceuticals Limited

Monday, 16 January 2017 11:54

AH: WILEX Signs Antibody License Agreement with Telix Pharmaceuticals Limited

Wednesday, 25 January 2017 11:29

PR: WILEX AG: Subsidiary Heidelberg Pharma Exercises Option on BCMA Antibodies of the Max Delbrück Center and Signs License Agreement

Monday, 06 February 2017 10:06

AH: WILEX AG secures financing commitment from its main shareholder dievini

Thursday, 30 March 2017 12:29

PR: WILEX announces financial figures for the 2016 fiscal year and reports on course of business

Wednesday, 12 April 2017 12:28

PR: WILEX AG: Interim management statement on the first three months of 2017

Monday, 24 April 2017 11:07

AH: WILEX AG plans rights issue using authorised capital

Thursday, 11 May 2017 12:28

PR: WILEX AG successfully completes rights issue

Monday, 19 June 2017 12:27

PR: WILEX AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates

Monday, 19 June 2017 13:07

AH: WILEX AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates

Thursday, 13 July 2017 12:27

PR: WILEX reports first half 2017 results

Wednesday, 20 September 2017 12:16

PR: WILEX AG: Subsidiary Heidelberg Pharma to Present the Proprietary ATAC Technology Platform at the Annual World ADC Summit

Tuesday, 26 September 2017 12:59

PR: WILEX AG: subsidiary Heidelberg Pharma becomes Runner Up in the category Best New Drug Developer at Annual World ADC Award 2017

Monday, 09 October 2017 13:02

AH: WILEX AG announces adjustment of guidance

Monday, 09 October 2017 13:04

PR: WILEX AG: Interim management statement for the first nine months of 2017

Thursday, 19 October 2017 13:09

PR: WILEX AG successfully completes change of name to Heidelberg Pharma AG

Thursday, 26 October 2017 12:52

Heidelberg Pharma AG: Partner RedHill Announces Orphan Drug Designation for MESUPRON

Friday, 03 November 2017 13:32

AH: Heidelberg Pharma AG plans capital measure to fund its ATAC development programs

Monday, 13 November 2017 16:57

PR: Heidelberg Pharma AG announces results from research collaboration with Heidelberg University and the DKFZ to be presented at ASH Annual Meeting

Thursday, 16 November 2017 19:48

AH: Heidelberg Pharma AG announces subscription price for new shares and conversion price for convertible bonds from ongoing capital measure

Tuesday, 21 November 2017 13:20

AH: Heidelberg Pharma AG raises approximately EUR 34.4 million from capital measure

Tuesday, 21 November 2017 13:58

PM: Heidelberg Pharma AG raises approximately EUR 34.4 million from capital measure

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.